Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reata Pharmaceuticals
Biotech
Biogen's top dealmaker is keen on rare disease meds
Biogen executive Adam Keeney, Ph.D., says 2024 is about executing after last year was about trimming costs and fortifying the portfolio.
Max Bayer
Mar 5, 2024 10:20am
Amgen poaches Moderna CMO—Chutes & Ladders
Jun 16, 2023 9:30am
Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
May 10, 2023 10:22am
FDA scraps AdComm for Reata's rare disease candidate
Oct 14, 2022 9:30am
Reata has wait for FDA ataxia drug decision delayed by 3 months
Aug 9, 2022 9:52am
FDA rejects Reata’s treatment for chronic kidney disease
Feb 28, 2022 11:41am